Al-Razi Medical Co. (9572.SR)
SAR 55.9
(2.57%)
SAR 55.9
(2.57%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 61.33 Million | 52.39 Million | 45.18 Million |
| Cost of Revenue | 47.26 Million | 38.83 Million | 33.97 Million |
| Gross Profit | 14.07 Million | 13.55 Million | 11.2 Million |
| Operating Expenses | 12.26 Million | 10.66 Million | 8.56 Million |
| Selling, General and Administrative Expenses | 12.26 Million | 10.66 Million | 8.56 Million |
| Research and Development Expenses | - | - | - |
| Other Expenses | -42.88 Thousand | 151.86 Thousand | - |
| Cost and Expenses | 59.91 Million | 49.5 Million | 42.53 Million |
| Operating Income | 1.81 Million | 2.89 Million | 2.64 Million |
| Interest Expense | 475.05 Thousand | 300.6 Thousand | 595.07 Thousand |
| Income Tax Expense | 399.73 Thousand | 410.71 Thousand | 370.14 Thousand |
| Earnings before Tax | 1.08 Million | 2.42 Million | 2.53 Million |
| Net Income | 685.96 Thousand | 2.01 Million | 2.16 Million |
| Earnings Per Share Basic | 0.45 | 1.33 | 1.42 |
| Earnings Per Share Diluted | 0.45 | 1.33 | 1.42 |
| Weighted Average Shares Outstanding | 1.52 Million | 1.52 Million | 1.52 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.52 Million | 1.52 Million | 1.52 Million |
| Gross Margin | 0.23 | 0.26 | 0.25 |
| EBIT Margin | 0.09 | 0.11 | 0.10 |
| Profit Margin | 0.01 | 0.04 | 0.05 |
| EBITDA | 5.64 Million | 5.72 Million | 5.12 Million |
| Earnings Before Tax Margin | 0.03 | 0.06 | 0.06 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 15.6 Million | 15.6 Million | 15.39 Million | 61.33 Million | 15.39 Million | 15.27 Million |
| Cost of Revenue | 11.5 Million | 11.5 Million | 11.32 Million | 47.26 Million | 11.32 Million | 10.69 Million |
| Gross Profit | 4.09 Million | 4.09 Million | 4.07 Million | 14.07 Million | 4.07 Million | 4.57 Million |
| Operating Expenses | 3.97 Million | 3.97 Million | 3.86 Million | 12.26 Million | 3.86 Million | 4.08 Million |
| Selling, General and Administrative Expenses | 3.97 Million | 3.97 Million | 3.88 Million | - | 3.88 Million | 4.08 Million |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | -1.00 | -1.00 | -16.6 Thousand | 182.95 Thousand | -16.6 Thousand | 1.00 |
| Cost and Expenses | 15.48 Million | 15.48 Million | 15.18 Million | 59.52 Million | 15.18 Million | 14.77 Million |
| Operating Income | 113.98 Thousand | 113.98 Thousand | 207.79 Thousand | 1.81 Million | 207.79 Thousand | 494.6 Thousand |
| Interest Expense | 252.61 Thousand | - | - | 475.05 Thousand | - | - |
| Income Tax Expense | 75 Thousand | 75 Thousand | 99.21 Thousand | 399.73 Thousand | 99.21 Thousand | 100.65 Thousand |
| Earnings before Tax | 80.06 Thousand | 80.06 Thousand | 139.03 Thousand | 1.08 Million | 139.03 Thousand | 403.81 Thousand |
| Net Income | 5064.00 | 5064.00 | 39.82 Thousand | 685.96 Thousand | 39.82 Thousand | 303.15 Thousand |
| Earnings Per Share Basic | 0.00 | 0.00 | 0.03 | - | 0.03 | 0.20 |
| Earnings Per Share Diluted | 0.00 | 0.00 | 0.03 | - | 0.03 | 0.20 |
| Weighted Average Shares Outstanding | 1.52 Million | 1.52 Million | 1.52 Million | 1.52 Million | 1.52 Million | 1.52 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.52 Million | 1.52 Million | 1.52 Million | 1.52 Million | 1.52 Million | 1.52 Million |
| Gross Margin | 0.26 | 0.26 | 0.26 | 0.23 | 0.26 | 0.30 |
| EBIT Margin | 0.03 | 0.03 | 0.04 | - | 0.04 | 0.06 |
| Profit Margin | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 |
| EBITDA | 512.13 Thousand | 512.13 Thousand | 558.69 Thousand | - | 558.69 Thousand | 841.07 Thousand |
| Earnings Before Tax Margin | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 | 0.03 |
LMPX
NTV
KOGMF
ACAB
600668
ASHCAP